Aquestive therapeutics spotlights its innovative epinephrine delivery pipeline at virtual investor day

Warren, n.j., sept. 27, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst) (“aquestive” or the “company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today hosted a virtual investor day highlighting the company's pipeline inclusive of anaphylm™ (epinephrine) sublingual film and aqst-108 (epinephrine) topical gel, both product candidates emerging from the company's adrenaverse™ epinephrine prodrug platform. the event included presentations by members of the aquestive management team and by distinguished key opinion leader j. david farrar, phd, associate professor, immunology/molecular biology, ut southwestern medical center.
AQST Ratings Summary
AQST Quant Ranking